Transaxillary compared with transcarotid ...
Document type :
Article dans une revue scientifique: Article original
DOI :
PMID :
Permalink :
Title :
Transaxillary compared with transcarotid access for tavr: a propensity-matched comparison from a french multicenter registry
Author(s) :
Debry, Nicolas [Auteur]
Récepteurs nucléaires, maladies cardiovasculaires et diabète - U 1011 [RNMCD]
Trimech, Talel Raouf [Auteur]
Pôle des Cardiopathies Congénitales du Nouveau-Né à L'adulte - Centre Constitutif Cardiopathies Congénitales Complexes M3C, Groupe Hospitalier Paris Saint-Joseph, Hôpital Marie-Lannelongue, Inserm U999, Université Paris-Saclay
Gandet, Thomas [Auteur]
Centre Hospitalier Régional Universitaire [Montpellier] [CHRU Montpellier]
Vincent, Flavien [Auteur]
Récepteurs nucléaires, maladies cardiovasculaires et diabète - U 1011 [RNMCD]
Hysi, Ilir [Auteur]
Centre Hospitalier de Lens
Delhaye, Cedric [Auteur]
Institut Coeur Poumon [CHU Lille]
Cayla, Guillaume [Auteur]
Centre Hospitalier Universitaire de Nîmes [CHU Nîmes]
Koussa, Mohamad [Auteur]
Institut Coeur Poumon [CHU Lille]
Juthier, Francis [Auteur]
Récepteurs nucléaires, Maladies Cardiovasculaires et Diabète (RNMCD) - U1011
Leclercq, Florence [Auteur]
Centre Hospitalier Régional Universitaire [Montpellier] [CHRU Montpellier]
Pecheux, Max [Auteur]
Centre Hospitalier de Lens
Ghostine, Said [Auteur]
Hôpital Marie-Lannelongue
Labreuche, Julien [Auteur]
Santé Publique : épidémiologie et qualité des soins [EA 2694]
Modine, Thomas [Auteur]
Institut Coeur Poumon [CHU Lille]
Van Belle, Eric [Auteur]
Récepteurs nucléaires, Maladies Cardiovasculaires et Diabète (RNMCD) - U1011
Récepteurs nucléaires, maladies cardiovasculaires et diabète - U 1011 [RNMCD]
Trimech, Talel Raouf [Auteur]
Pôle des Cardiopathies Congénitales du Nouveau-Né à L'adulte - Centre Constitutif Cardiopathies Congénitales Complexes M3C, Groupe Hospitalier Paris Saint-Joseph, Hôpital Marie-Lannelongue, Inserm U999, Université Paris-Saclay
Gandet, Thomas [Auteur]
Centre Hospitalier Régional Universitaire [Montpellier] [CHRU Montpellier]
Vincent, Flavien [Auteur]
Récepteurs nucléaires, maladies cardiovasculaires et diabète - U 1011 [RNMCD]
Hysi, Ilir [Auteur]
Centre Hospitalier de Lens
Delhaye, Cedric [Auteur]
Institut Coeur Poumon [CHU Lille]
Cayla, Guillaume [Auteur]
Centre Hospitalier Universitaire de Nîmes [CHU Nîmes]
Koussa, Mohamad [Auteur]
Institut Coeur Poumon [CHU Lille]
Juthier, Francis [Auteur]
Récepteurs nucléaires, Maladies Cardiovasculaires et Diabète (RNMCD) - U1011
Leclercq, Florence [Auteur]
Centre Hospitalier Régional Universitaire [Montpellier] [CHRU Montpellier]
Pecheux, Max [Auteur]
Centre Hospitalier de Lens
Ghostine, Said [Auteur]
Hôpital Marie-Lannelongue
Labreuche, Julien [Auteur]
Santé Publique : épidémiologie et qualité des soins [EA 2694]
Modine, Thomas [Auteur]
Institut Coeur Poumon [CHU Lille]
Van Belle, Eric [Auteur]
Récepteurs nucléaires, Maladies Cardiovasculaires et Diabète (RNMCD) - U1011
Journal title :
EuroIntervention . journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology
Abbreviated title :
EuroIntervention
Volume number :
16
Publisher :
EAPCI
Publication date :
2020-04-21
ISSN :
1969-6213
Keyword(s) :
aortic stenosis
other
TAVR
subclavian
other
TAVR
subclavian
HAL domain(s) :
Sciences du Vivant [q-bio]
English abstract : [en]
Aims: No randomised study comparing the outcomes of transcarotid (TC) and transaxillary (TAx) TAVR has been conducted to date. The purpose of this study was to understand which approach should be the preferred alternative ...
Show more >Aims: No randomised study comparing the outcomes of transcarotid (TC) and transaxillary (TAx) TAVR has been conducted to date. The purpose of this study was to understand which approach should be the preferred alternative by comparing their outcomes using a propensity-matched comparison in a French multicentre registry. Methods and results: From 2010 to 2018, a French multicentre prospective registry included 502 patients, with 374 undergoing TC-TAVR and 128 TAx-TAVR for symptomatic aortic stenosis. Patients treated through TAx access were matched 1:2 with patients treated through the TC route by using a propensity score (20 clinical, anatomical and procedural variables) and by date of the procedure. The first outcome was mortality at one-month follow-up. The second outcome was one-month stroke/transient ischaemic attack (TIA). In propensity-matched analyses, the incidence of the primary outcome was similar in the TAx and TC groups (TAx 5.5% vs TC 4.5%, OR 1.23, 95% CI: 0.40-3.70). The secondary outcome was similar in TAx (3.2%) and TC (6.8%, OR 0.52, 95% CI: 0.14-1.84). Minor bleeding (2.7% vs 9.3%, OR 0.26, 95% CI: 0.07-0.92) and main access haematoma (3.6% vs 10.3%, OR 0.034, 95% CI: 0.09-0.92) were significantly more frequent with the TC access. One-month clinical efficacy and safety and one-year mortality did not differ according to the different routes. Conclusions: One-month mortality, one-month stroke/TIA and one-year mortality are similar with TAx-TAVR and TC-TAVR. However, TC-TAVR is accompanied by more minor bleeding and main access haematoma compared with the transaxillary route.Show less >
Show more >Aims: No randomised study comparing the outcomes of transcarotid (TC) and transaxillary (TAx) TAVR has been conducted to date. The purpose of this study was to understand which approach should be the preferred alternative by comparing their outcomes using a propensity-matched comparison in a French multicentre registry. Methods and results: From 2010 to 2018, a French multicentre prospective registry included 502 patients, with 374 undergoing TC-TAVR and 128 TAx-TAVR for symptomatic aortic stenosis. Patients treated through TAx access were matched 1:2 with patients treated through the TC route by using a propensity score (20 clinical, anatomical and procedural variables) and by date of the procedure. The first outcome was mortality at one-month follow-up. The second outcome was one-month stroke/transient ischaemic attack (TIA). In propensity-matched analyses, the incidence of the primary outcome was similar in the TAx and TC groups (TAx 5.5% vs TC 4.5%, OR 1.23, 95% CI: 0.40-3.70). The secondary outcome was similar in TAx (3.2%) and TC (6.8%, OR 0.52, 95% CI: 0.14-1.84). Minor bleeding (2.7% vs 9.3%, OR 0.26, 95% CI: 0.07-0.92) and main access haematoma (3.6% vs 10.3%, OR 0.034, 95% CI: 0.09-0.92) were significantly more frequent with the TC access. One-month clinical efficacy and safety and one-year mortality did not differ according to the different routes. Conclusions: One-month mortality, one-month stroke/TIA and one-year mortality are similar with TAx-TAVR and TC-TAVR. However, TC-TAVR is accompanied by more minor bleeding and main access haematoma compared with the transaxillary route.Show less >
Language :
Anglais
Audience :
Internationale
Popular science :
Non
Administrative institution(s) :
CHU Lille
Inserm
Institut Pasteur de Lille
Université de Lille
Inserm
Institut Pasteur de Lille
Université de Lille
Collections :
Research team(s) :
Troubles cognitifs dégénératifs et vasculaires
Submission date :
2021-06-23T13:48:41Z
2024-03-27T09:13:37Z
2024-03-27T09:13:37Z